HRP20240414T1 - Supstituirani indazoli, postupak za njihovu pripremu, farmaceutske formulacije koje ih sadrže i njihova upotreba za pripremu lijekova - Google Patents
Supstituirani indazoli, postupak za njihovu pripremu, farmaceutske formulacije koje ih sadrže i njihova upotreba za pripremu lijekova Download PDFInfo
- Publication number
- HRP20240414T1 HRP20240414T1 HRP20240414TT HRP20240414T HRP20240414T1 HR P20240414 T1 HRP20240414 T1 HR P20240414T1 HR P20240414T T HRP20240414T T HR P20240414TT HR P20240414 T HRP20240414 T HR P20240414T HR P20240414 T1 HRP20240414 T1 HR P20240414T1
- Authority
- HR
- Croatia
- Prior art keywords
- pain
- alkyl
- disorders
- hydrogen
- methyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 4
- 150000002473 indoazoles Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000002193 Pain Diseases 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- -1 2-hydroxypropan-2-yl Chemical group 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 229910052731 fluorine Inorganic materials 0.000 claims 9
- 239000011737 fluorine Substances 0.000 claims 9
- 238000011282 treatment Methods 0.000 claims 9
- 201000009273 Endometriosis Diseases 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 7
- 238000011321 prophylaxis Methods 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical class 0.000 claims 4
- 208000000094 Chronic Pain Diseases 0.000 claims 4
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 4
- 208000004454 Hyperalgesia Diseases 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 201000005671 spondyloarthropathy Diseases 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 206010065390 Inflammatory pain Diseases 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- 206010051244 Dyschezia Diseases 0.000 claims 2
- 208000005171 Dysmenorrhea Diseases 0.000 claims 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 2
- 208000004483 Dyspareunia Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 208000035154 Hyperesthesia Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 208000008930 Low Back Pain Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 206010065347 Premenstrual pain Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 206010053552 allodynia Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 206010013990 dysuria Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 2
- 201000007094 prostatitis Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- KCKMLTMGAUALMW-UHFFFAOYSA-N 6-(difluoromethyl)-N-[6-(2-hydroxypropan-2-yl)-2-(2-methylsulfonylethyl)indazol-5-yl]pyridine-2-carboxamide Chemical compound FC(C1=CC=CC(=N1)C(=O)NC1=CC2=CN(N=C2C=C1C(C)(C)O)CCS(=O)(=O)C)F KCKMLTMGAUALMW-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- OQAMEEFUUFJZRS-UHFFFAOYSA-N N-[6-(2-hydroxypropan-2-yl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide Chemical compound OC(C)(C)C=1C(=CC2=CN(N=C2C=1)CCS(=O)(=O)C)NC(=O)C1=NC(=CC=C1)C(F)(F)F OQAMEEFUUFJZRS-UHFFFAOYSA-N 0.000 claims 1
- PHQVOBKAZNOWIV-UHFFFAOYSA-N N-[6-(2-hydroxypropan-2-yl)-2-(3-methylsulfonylpropyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide Chemical compound OC(C)(C)C=1C(=CC2=CN(N=C2C=1)CCCS(=O)(=O)C)NC(=O)C1=NC(=CC=C1)C(F)(F)F PHQVOBKAZNOWIV-UHFFFAOYSA-N 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000623 heterocyclic group Chemical class 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical class 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (22)
1. Spojevi opće formule (I)
[image]
u kojoj:
R1 je C1-C6-alkil, gdje je C1-C6-alkil radikal monosupstituiran s radikalom R7SO2 ili R7SO ili
gdje je radikal C1-C6-alkil polisupstituiran s radikalom R7SO2 ili R7SO i mono- ili polisupstituiran s halogenom, hidroksilom, nesupstituiranim ili mono- ili poli-halogen-supstituiranim C3-C6-cikloalkilom, radikal R6 ili R8O;
R2 i R3 uvijek imaju istu definiciju i oba su ili vodik ili C1-C6-alkil;
R4 je halogen, cijano, nesupstituiran ili pojedinačno ili višestruko, identično ili različito supstituiran C1-C6-alkil ili nesupstituiran ili pojedinačno ili višestruko, identično ili različito supstituiran C3-C6-cikloalkil, i supstituenti su odabrani iz skupine koja sadrži halogen i hidroksil;
R5 je vodik, halogen ili nesupstituiran ili mono- ili poli-halogen-supstituiran C1-C6-alkil;
R6 je nesupstituiran ili mono- ili di-metil-supstituiran monociklički, zasićeni heterocikl koji ima 4 do 6 atoma u prstenu, koji sadrži heteroatom ili heteroskupinu iz skupine O, S, SO i SO2;
R7 je C1-C6-alkil, gdje je radikal C1-C6-alkil nesupstituiran ili mono- ili polisupstituiran identično ili različito s halogenom, hidroksilom ili C3-C6-cikloalkilom; ili R7 je C3-C6-cikloalkil;
R8 je C1-C6-alkil, gdje je radikal C1-C6-alkil nesupstituiran ili mono- ili polisupstituiran identično ili različito sa halogenom;
i dijastereomeri, enantiomeri, soli, solvati ili solvati njihovih soli.
2. Spojevi prema zahtjevu 1, naznačeni time što
R1 je C1-C6-alkil, gdje je C1-C6-alkil radikal monosupstituiran s R7SO2 ili R7SO ili
gdje je radikal C1-C6-alkil polisupstituiran s radikalom R7SO2 ili R7SO i mono- ili polisupstituiran s fluorom, hidroksilom, radikalom R6 ili R8O;
R2 i R3 uvijek imaju istu definiciju i oba su ili vodik ili C1-C3-alkil;
R4 je halogen, cijano ili C1-C3-alkil, gdje je radikal C1-C3-alkil nesupstituiran ili mono- ili polisupstituiran identično ili različito s halogenom ili hidroksilom;
R5 je vodik, fluor, klor ili C1-C3-alkil;
R6 je oksetanil ili tetrahidrofuranil;
R7 je C1-C4-alkil, gdje je C1-C4-alkil radikal nesupstituiran ili monosupstituiran s hidroksilom ili s ciklopropilom ili supstituiran s tri atoma fluora;
R8 je nesupstituiran C1-C4-alkil radikal ili trifluor-supstituiran radikal C1-C4-alkil.
3. Spojevi prema zahtjevu 1 ili 2, naznačeni time što R4 je difluormetil, trifluormetil ili metil.
4. Spojevi prema zahtjevu 1, 2 ili 3, naznačeni time što R5 je vodik ili fluor.
5. Spojevi prema zahtjevu 1, 2, 3 ili 4, naznačeni time što R2 i R3 oba su ili vodik ili metil.
6. Spojevi prema zahtjevu 2, naznačeni time što
R1 je C2-C6-alkil, gdje je radikal C2-C6-alkil monosupstituiran s R7SO2;
R2 i R3 uvijek imaju istu definiciju i oba su ili vodik ili metil;
R4 je nesupstituiran ili mono- ili poli-halogen-supstituiran C1-C3-alkil radikal ili a C1-C3-alkil radikal supstituiran s jednom hidroksilnom skupinom ili radikal C1-C3-alkil supstituiran s jednom hidroksilnom skupinom i tri atoma fluora;
R5 je vodik, fluor ili C1-C3-alkil;
R7 je C1-C3-alkil.
7. Spojevi prema zahtjevu 6, naznačeni time što
R1 je a metil-SO2-supstituiran C2-C4-alkil radikal;
R2 i R3 uvijek imaju istu definiciju i oba su vodik ili metil;
R4 je metil, etil, trifluor-C1-C3-alkil, difluor-C1-C3-alkil, hidroksimetil, 1-hidroksietil, 2-hidroksipropan-2-il i 2,2,2-trifluor-1-hidroksietil;
R5 je vodik, fluor ili metil.
8. Spojevi prema zahtjevu 7, naznačeni time što
R1 je 2-(metilsulfonil)etil ili 3-(metilsulfonil)propil;
R2 i R3 oba su metil ili vodik;
R4 je difluormetil, trifluormetil ili metil;
R5 je vodik ili fluor.
9. Spojevi prema zahtjevu 8, naznačeni time što
R1 je 3-(metilsulfonil)propil ili 2-(metilsulfonil)etil;
R2 i R3 oba su metil;
R4 je difluormetil ili trifluormetil;
R5 je vodik.
10. Spojevi prema zahtjevu 8, naznačeni time što
R1 je 3-(metilsulfonil)propil ili 2-(metilsulfonil)etil;
R2 i R3 oba su metil;
R4 je metil;
R5 je fluor, gdje R5 je u orto položaju prema R4.
11. Spojevi prema zahtjevima 1-10 kako slijedi:
1) N-{6-(2-hidroksipropan-2-il)-2-[3-(metilsulfonil)propil]-2H-indazol-5-il}-6-(trifluormetil)piridin-2-karboksamid
2) N-{6-(2-hidroksipropan-2-il)-2-[2-(metilsulfonil)etil]-2H-indazol-5-il}-6-(trifluormetil)piridin-2-karboksamid
3) 6-(difluormetil)-N-{6-(2-hidroksipropan-2-il)-2-[2-(metilsulfonil)etil]-2H-indazol-5-il}piridin-2-karboksamid.
12. Spoj opće formule (I) kako je definiran u bilo kojem od zahtjeva 1 do 11 naznačen time što je za upotrebu u postupku liječenja i/ili profilakse bolesti.
13. Spoj opće formule (I) kako je definiran u bilo kojem od zahtjeva 1 do 11 naznačen time što je za upotrebu u postupku liječenja i/ili profilakse neoplastičnih poremećaja, dermatoloških poremećaja, ginekoloških poremećaja, kardiovaskularnih poremećaja, plućnih poremećaja, oftalmoloških poremećaja, neuroloških poremećaja, metaboličkih poremećaja, jetrenih poremećaja, upalnih poremećaja, autoimunih poremećaja i boli.
14. Spoj opće formule (I) kako je definiran u bilo kojem od zahtjeva 1 do 11 naznačen time što je za upotrebu u postupku liječenja i/ili profilakse limfoma, makularne degeneracije, psorijaze, eritemskog lupusa, multiple skleroze, KOPB-a, gihta, NASH-a, fibroze jetre, inzulinske rezistencije, metaboličkog sindroma, spondiloartritisa i reumatoidnog artritisa, endometrioze i boli povezane s endometriozom i drugih simptoma povezanih s endometriozom kao što je dismenoreja, dispareunija, disurija i dishezija.
15. Spoj opće formule (I) kako je definiran u bilo kojem od zahtjeva 1 do 11 naznačen time što je za upotrebu u postupku liječenja i/ili profilakse boli uključujući akutnu, kroničnu, upalnu i neuropatsku bol, poželjno hiperalgezije, alodinije, boli od artritisa (kao što je osteoartritis, reumatoidni artritis i spondiloartritis), predmenstrualne boli, boli povezane s endometriozom, postoperativne boli, boli od intersticijskog cistitisa, CRPS (kompleksnog regionalnog bolnog sindroma), trigeminalne neuralgije, boli od prostatitisa, boli uzrokovane ozljedama leđne moždine, boli uzrokovane upalom, boli u donjem dijelu leđa, boli uzrokovane rakom, boli povezane s kemoterapijom, neuropatije uzrokovane liječenjem HIV-a, boli uzrokovane opeklinama i kronične boli.
16. Spoj opće formule (I) kako je definiran u bilo kojem od zahtjeva 1 do 11 naznačen time što je za upotrebu kao lijek.
17. Spoj opće formule (I) za upotrebu prema zahtjevu 16, naznačen time što se lijek koristi za liječenje i/ili profilaksu neoplastičnih poremećaja, dermatoloških poremećaja, ginekoloških poremećaja, kardiovaskularnih poremećaja, plućnih poremećaja, oftalmoloških poremećaja, neuroloških poremećaja, metaboličkih poremećaja, jetrenih poremećaja, upalnih poremećaja, autoimunih poremećaja i boli.
18. Spoj opće formule (I) za upotrebu prema zahtjevima 16 i 17 za liječenje i/ili profilaksu limfoma, makularne degeneracije, psorijaze, eritemskog lupusa, multiple skleroze, KOPB-a, gihta, NASH-a, fibroze jetre, inzulinske rezistencije, metaboličkog sindroma, spondiloartritisa i reumatoidnog artritisa, endometrioze i boli povezane s endometriozom i drugih simptoma povezanih s endometriozom kao što je dismenoreja, dispareunija, disurija i dishezija.
19. Spoj opće formule (I) za upotrebu prema zahtjevima 16 i 17 za liječenje i/ili profilaksu boli uključujući akutnu, kroničnu, upalnu i neuropatsku bol, poželjno hiperalgezije, alodinije, boli od artritisa (kao što je osteoartritis, reumatoidni artritis i spondiloartritis), predmenstrualne boli, boli povezane s endometriozom, postoperativne boli, boli od intersticijskog cistitisa, CRPS (kompleksnog regionalnog bolnog sindroma), trigeminalne neuralgije, boli od prostatitisa, boli uzrokovane ozljedama leđne moždine, boli uzrokovane upalom, boli u donjem dijelu leđa, boli uzrokovane rakom, boli povezane s kemoterapijom, neuropatije uzrokovane liječenjem HIV-a, boli uzrokovane opeklinama i kronične boli.
20. Lijek koji sadrži spoj formule (I) kako je definiran u bilo kojem od zahtjeva 1 do 11 u kombinaciji s inertnom, netoksičnom, farmaceutski prikladnom pomoćnom tvari.
21. Postupak za pripremu spojeva opće formule (III) iz spojeva opće formule (II)
[image]
u kojima
R1 je 2-(metilsulfonil)etil ili 3-(metilsulfonil)propil;
R4 je difluormetil, trifluormetil ili metil;
R5 je vodik ili fluor;
reakcijom (II) s odgovarajućim supstituiranim alkil halogenidima ili alkil 4-metilbenzensulfonatima u prisutnosti kalijevog karbonata.
22. Spojevi opće formule (III):
[image]
u kojoj
R1 je 2-(metilsulfonil)etil ili 3-(metilsulfonil)propil;
R4 je difluormetil, trifluormetil ili metil; i
R5 je vodik ili fluor,
i dijastereomeri, enantiomeri, soli, solvati ili solvati njihovih soli.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14195032 | 2014-11-26 | ||
EP19191936.4A EP3674298B9 (de) | 2014-11-26 | 2015-11-25 | Substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20240414T1 true HRP20240414T1 (hr) | 2024-06-21 |
Family
ID=51982455
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20240414TT HRP20240414T1 (hr) | 2014-11-26 | 2015-11-25 | Supstituirani indazoli, postupak za njihovu pripremu, farmaceutske formulacije koje ih sadrže i njihova upotreba za pripremu lijekova |
HRP20200974TT HRP20200974T1 (hr) | 2014-11-26 | 2020-06-19 | Supstituirani indazoli, postupak za njihovu pripremu, farmaceutske formulacije koji ih sadrže i njihova upotreba za pripravu lijekova |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200974TT HRP20200974T1 (hr) | 2014-11-26 | 2020-06-19 | Supstituirani indazoli, postupak za njihovu pripremu, farmaceutske formulacije koji ih sadrže i njihova upotreba za pripravu lijekova |
Country Status (42)
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160115933A (ko) | 2014-01-10 | 2016-10-06 | 오리진 디스커버리 테크놀로지스 리미티드 | Irak4 억제제로서의 인다졸 화합물 |
IL294895B2 (en) | 2014-01-13 | 2023-10-01 | Aurigene Oncology Ltd | History of bicyclic heterocyclyls as IRAK4 inhibitors |
JO3705B1 (ar) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
WO2016174183A1 (en) * | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
EP3195865A1 (de) * | 2016-01-25 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Kombinationen von irak4 inhibitoren und btk inhibitoren |
CA3016364A1 (en) | 2016-03-03 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
EP3219329A1 (en) * | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
SG11201809172WA (en) * | 2016-04-29 | 2018-11-29 | Bayer Pharma AG | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide |
EA035867B1 (ru) * | 2016-04-29 | 2020-08-24 | Байер Фарма Акциенгезельшафт | Синтез индазолов |
AU2017257211B2 (en) * | 2016-04-29 | 2021-05-27 | Bayer Pharma Aktiengesellschaft | Polymorphic form of N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide |
RU2743170C2 (ru) * | 2016-06-01 | 2021-02-15 | Байер Энимал Хелс Гмбх | Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных |
CA3025826A1 (en) * | 2016-06-01 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
AU2017322427B2 (en) | 2016-09-09 | 2021-12-23 | Incyte Corporation | Pyrazolopyridine derivatives as HPK1 modulators and uses thereof for the treatment of cancer |
US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
AR109595A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
WO2018060072A1 (de) | 2016-09-29 | 2018-04-05 | Bayer Pharma Aktiengesellschaft | Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
KR20240019391A (ko) | 2017-03-31 | 2024-02-14 | 오리진 온콜로지 리미티드 | 혈액 장애를 치료하기 위한 화합물 및 조성물 |
WO2018200786A1 (en) * | 2017-04-26 | 2018-11-01 | Yale University | Compositions and methods for treating vitiligo |
CA3072493A1 (en) | 2017-08-16 | 2019-02-21 | Vanderbilt University | Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
JP2021515033A (ja) | 2018-02-20 | 2021-06-17 | インサイト・コーポレイションIncyte Corporation | がんを治療するためのhpk1阻害剤としてのn−(フェニル)−2−(フェニル)ピリミジン−4−カルボキサミド誘導体及び関連化合物 |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
CN116640118A (zh) | 2018-06-27 | 2023-08-25 | 豪夫迈·罗氏有限公司 | 放射性标记的大麻素受体2配体 |
TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
CN110835338A (zh) * | 2018-08-17 | 2020-02-25 | 浙江海正药业股份有限公司 | 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途 |
CN112513027B (zh) * | 2018-08-17 | 2024-03-29 | 浙江海正药业股份有限公司 | 吲唑胺类衍生物及其制备方法和其在医药上的用途 |
US11111247B2 (en) | 2018-09-25 | 2021-09-07 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
CN111362920B (zh) * | 2018-12-25 | 2024-06-07 | 上海美悦生物科技发展有限公司 | 一种作为irak抑制剂的化合物 |
US20220204473A1 (en) * | 2018-12-25 | 2022-06-30 | Shanghai Meiyue Biotech Development Co., Ltd. | Compound as irak inhibitor |
CN111499612B (zh) * | 2019-01-30 | 2022-12-30 | 上海美悦生物科技发展有限公司 | 一种作为irak抑制剂的化合物及其制备方法和用途 |
CN111560012B (zh) * | 2019-02-14 | 2023-06-23 | 上海美悦生物科技发展有限公司 | 一种作为irak抑制剂的化合物 |
CN111793064B (zh) * | 2019-04-02 | 2023-06-23 | 上海美悦生物科技发展有限公司 | 一种作为irak抑制剂的化合物及其制备方法和用途 |
CN113825755B (zh) * | 2019-06-26 | 2023-04-25 | 南京明德新药研发有限公司 | 作为irak4抑制剂的咪唑并吡啶类化合物 |
TW202116735A (zh) * | 2019-06-27 | 2021-05-01 | 美商百健Ma公司 | 2h—吲唑衍生物及其在疾病治療中之用途 |
WO2021007477A1 (en) | 2019-07-11 | 2021-01-14 | E-Scape Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
JP2022543155A (ja) | 2019-08-06 | 2022-10-07 | インサイト・コーポレイション | Hpk1阻害剤の固体形態 |
TWI832010B (zh) * | 2019-09-24 | 2024-02-11 | 大陸商上海美悦生物科技發展有限公司 | Irak抑制劑及其製備方法和用途 |
CN111072634B (zh) * | 2020-01-03 | 2022-07-22 | 中国医科大学 | 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用 |
CN113521079A (zh) * | 2020-04-20 | 2021-10-22 | 上海领泰生物医药科技有限公司 | Irak4抑制剂在治疗ali/ards中的应用 |
US11866405B2 (en) | 2020-12-10 | 2024-01-09 | Astrazeneca Ab | Substituted indazoles as IRAK4 inhibitors |
CN113278017B (zh) * | 2021-05-27 | 2023-03-28 | 上海应用技术大学 | 取代吲唑类化合物、制备方法、应用和包含其的组合物 |
CN113402499B (zh) | 2021-06-21 | 2022-05-13 | 上海勋和医药科技有限公司 | 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途 |
WO2023283372A1 (en) * | 2021-07-07 | 2023-01-12 | Biogen Ma Inc. | Compounds for targeting degradation of irak4 proteins |
WO2023098857A1 (zh) * | 2021-12-03 | 2023-06-08 | 武汉人福创新药物研发中心有限公司 | Irak4抑制剂及其用途 |
WO2024108010A1 (en) * | 2022-11-17 | 2024-05-23 | Bayer Animal Health Gmbh | Methods and compositions for control of pain and inflammation |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2246606B1 (es) | 2002-07-23 | 2007-06-01 | Izar Construcciones Navales S.A. | Unidad semi-sumergible auto-propulsada para transporte y engorde de peces vivos. |
KR20050026535A (ko) * | 2002-07-31 | 2005-03-15 | 쉐링 악티엔게젤샤프트 | Vegfr-2 및 vegfr-3 억제성 안트라닐아미도피리딘 |
WO2004113281A1 (en) | 2003-06-25 | 2004-12-29 | Je Il Pharmaceutical Co., Ltd. | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them |
WO2005082866A2 (en) | 2004-02-20 | 2005-09-09 | Pfizer Limited | Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists |
EP1828133A2 (en) | 2004-12-08 | 2007-09-05 | Warner-Lambert Company LLC | Methylene inhibitors of matrix metalloproteinase |
TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
GT200600411A (es) * | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
GB0518671D0 (en) * | 2005-09-13 | 2005-10-19 | Novartis Ag | Organic compounds |
US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
KR20090005296A (ko) | 2006-02-10 | 2009-01-13 | 서미트 코포레이션 피엘씨 | 뒤시엔느 근이영양증의 치료 |
TWI435863B (zh) | 2006-03-20 | 2014-05-01 | Nihon Nohyaku Co Ltd | N-2-(雜)芳基乙基甲醯胺衍生物及含該衍生物之蟲害防治劑 |
EP2045253A4 (en) | 2006-06-29 | 2013-01-23 | Nissan Chemical Ind Ltd | alpha-amino acid derivative and pharmaceutical agent containing it as an active ingredient |
CA2663100A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Indazole derivatives as modulators of interleukin-1 receptor-associated kinase |
FR2917735B1 (fr) | 2007-06-21 | 2009-09-04 | Sanofi Aventis Sa | Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique |
US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
WO2009117421A2 (en) | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
US20100094000A1 (en) | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
JP2013512878A (ja) * | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | 新規化合物 |
WO2011153588A1 (en) | 2010-06-10 | 2011-12-15 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
US20140113898A1 (en) | 2010-11-08 | 2014-04-24 | Zalicus Pharmaceuticals Ltd. | Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers |
PL2655357T3 (pl) * | 2010-12-20 | 2016-12-30 | Pochodne triazolowe indazolilowe jako inhibitory irak | |
WO2012107475A1 (en) | 2011-02-10 | 2012-08-16 | Syngenta Participations Ag | Microbiocidal pyrazole derivatives |
EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
CA2827311A1 (en) | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman-spirocyclic piperidine amides as modulators of ion channels |
WO2013106254A1 (en) | 2012-01-11 | 2013-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
WO2013174744A1 (en) | 2012-05-21 | 2013-11-28 | Bayer Pharma Aktiengesellschaft | Thienopyrimidines |
JP2015002717A (ja) | 2013-06-21 | 2015-01-08 | 住友ベークライト株式会社 | 蓋付き容器 |
TWI667233B (zh) * | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
KR20160115933A (ko) * | 2014-01-10 | 2016-10-06 | 오리진 디스커버리 테크놀로지스 리미티드 | Irak4 억제제로서의 인다졸 화합물 |
CA2952188A1 (en) | 2014-06-20 | 2015-12-23 | Aurigene Discovery Technologies Limited | Substituted indazole compounds as irak4 inhibitors |
JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
WO2016174183A1 (en) | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
EA201890307A1 (ru) | 2015-07-15 | 2018-10-31 | Ориджин Дискавери Текнолоджиз Лимитед | Индазольные и азаиндазольные соединения как ингибиторы irak-4 |
CA3016364A1 (en) | 2016-03-03 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
EP3219329A1 (en) | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
SG11201809172WA (en) | 2016-04-29 | 2018-11-29 | Bayer Pharma AG | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide |
AU2017257211B2 (en) | 2016-04-29 | 2021-05-27 | Bayer Pharma Aktiengesellschaft | Polymorphic form of N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide |
CA3025826A1 (en) | 2016-06-01 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
RU2743170C2 (ru) | 2016-06-01 | 2021-02-15 | Байер Энимал Хелс Гмбх | Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных |
-
2015
- 2015-11-23 JO JOP/2015/0287A patent/JO3705B1/ar active
- 2015-11-25 BR BR112017011005-9A patent/BR112017011005B1/pt active IP Right Grant
- 2015-11-25 JP JP2017528139A patent/JP6496823B2/ja active Active
- 2015-11-25 SI SI201532005T patent/SI3674298T1/sl unknown
- 2015-11-25 NZ NZ732126A patent/NZ732126A/en unknown
- 2015-11-25 RS RS20200564A patent/RS60284B1/sr unknown
- 2015-11-25 LT LTEP19191936.4T patent/LT3674298T/lt unknown
- 2015-11-25 SG SG10201903475TA patent/SG10201903475TA/en unknown
- 2015-11-25 CN CN201580073989.1A patent/CN107406416B/zh active Active
- 2015-11-25 SG SG11201704092YA patent/SG11201704092YA/en unknown
- 2015-11-25 ME MEP-2020-115A patent/ME03745B/me unknown
- 2015-11-25 UA UAA201706382A patent/UA120948C2/uk unknown
- 2015-11-25 CR CR20170220A patent/CR20170220A/es unknown
- 2015-11-25 CU CU2017000073A patent/CU24448B1/es unknown
- 2015-11-25 RS RS20240330A patent/RS65327B1/sr unknown
- 2015-11-25 EP EP23189515.2A patent/EP4260909A3/de active Pending
- 2015-11-25 AU AU2015352603A patent/AU2015352603B2/en active Active
- 2015-11-25 EA EA201791137A patent/EA032509B1/ru not_active IP Right Cessation
- 2015-11-25 BR BR122021002613-0A patent/BR122021002613B1/pt active IP Right Grant
- 2015-11-25 PT PT191919364T patent/PT3674298T/pt unknown
- 2015-11-25 PT PT158008284T patent/PT3224254T/pt unknown
- 2015-11-25 DK DK19191936.4T patent/DK3674298T3/da active
- 2015-11-25 SI SI201531182T patent/SI3224254T1/sl unknown
- 2015-11-25 CA CA2968614A patent/CA2968614C/en active Active
- 2015-11-25 PL PL15800828T patent/PL3224254T3/pl unknown
- 2015-11-25 EP EP19191936.4A patent/EP3674298B9/de active Active
- 2015-11-25 WO PCT/EP2015/077596 patent/WO2016083433A1/de active Application Filing
- 2015-11-25 ES ES15800828T patent/ES2796285T3/es active Active
- 2015-11-25 MX MX2017006910A patent/MX2017006910A/es unknown
- 2015-11-25 MX MX2020010623A patent/MX2020010623A/es unknown
- 2015-11-25 PE PE2017000922A patent/PE20171376A1/es unknown
- 2015-11-25 DK DK15800828.4T patent/DK3224254T3/da active
- 2015-11-25 MA MA41011A patent/MA41011B1/fr unknown
- 2015-11-25 LT LTEP15800828.4T patent/LT3224254T/lt unknown
- 2015-11-25 HR HRP20240414TT patent/HRP20240414T1/hr unknown
- 2015-11-25 KR KR1020177017079A patent/KR102083857B1/ko active IP Right Grant
- 2015-11-25 TN TN2017000226A patent/TN2017000226A1/en unknown
- 2015-11-25 HU HUE15800828A patent/HUE049341T2/hu unknown
- 2015-11-25 EP EP15800828.4A patent/EP3224254B1/de active Active
- 2015-11-25 FI FIEP19191936.4T patent/FI3674298T3/fi active
- 2015-11-25 UA UAA201909772A patent/UA123813C2/uk unknown
- 2015-11-25 US US15/529,996 patent/US10308634B2/en active Active
- 2015-11-25 SG SG10201903474PA patent/SG10201903474PA/en unknown
- 2015-11-25 CN CN201910670725.4A patent/CN110305109B/zh active Active
- 2015-11-26 AR ARP150103876A patent/AR102827A1/es active IP Right Grant
- 2015-11-26 UY UY0001036411A patent/UY36411A/es active IP Right Grant
- 2015-11-26 TW TW108137338A patent/TWI717061B/zh active
- 2015-11-26 TW TW104139563A patent/TWI689502B/zh active
-
2017
- 2017-05-09 IL IL25218517A patent/IL252185B/en active IP Right Grant
- 2017-05-25 PH PH12017500972A patent/PH12017500972A1/en unknown
- 2017-05-25 EC ECIEPI201732530A patent/ECSP17032530A/es unknown
- 2017-05-26 DO DO2017000127A patent/DOP2017000127A/es unknown
- 2017-05-26 NI NI201700063A patent/NI201700063A/es unknown
- 2017-05-26 CL CL2017001364A patent/CL2017001364A1/es unknown
- 2017-06-26 CO CONC2017/0005374A patent/CO2017005374A2/es unknown
-
2019
- 2019-04-05 US US16/377,025 patent/US10793545B2/en active Active
- 2019-06-20 IL IL267537A patent/IL267537B/en active IP Right Grant
- 2019-09-19 IL IL269444A patent/IL269444B/en active IP Right Grant
-
2020
- 2020-02-11 AU AU2020200979A patent/AU2020200979B2/en active Active
- 2020-06-05 CY CY20201100506T patent/CY1123815T1/el unknown
- 2020-06-19 HR HRP20200974TT patent/HRP20200974T1/hr unknown
- 2020-09-01 US US17/009,553 patent/US20210053941A1/en not_active Abandoned
-
2022
- 2022-07-20 US US17/869,673 patent/US12006303B2/en active Active
- 2022-07-20 US US17/869,674 patent/US12006304B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20240414T1 (hr) | Supstituirani indazoli, postupak za njihovu pripremu, farmaceutske formulacije koje ih sadrže i njihova upotreba za pripremu lijekova | |
MX2020010737A (es) | Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b. | |
PH12018500088A1 (en) | Substituted tricyclics and method of use | |
CY1124084T1 (el) | Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων | |
MX2021009673A (es) | Moduladores de ror-gamma. | |
PH12017500367B1 (en) | Compounds that inhibit mcl-1 protein | |
JP2016507581A5 (hr) | ||
WO2016012965A3 (en) | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof | |
MX2022003102A (es) | Degradadores bifuncionales de brd9 y sus metodos de uso. | |
NZ766530A (en) | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | |
AR111315A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
RU2018113718A (ru) | Новые соединения | |
PH12018501236A1 (en) | Pharmaceutical composition comprising a potent inhibitor urat1 | |
HRP20180973T1 (hr) | Supstituirani tiazolski ili oksazolski antagonisti p2x7 receptora | |
PH12019550226A1 (en) | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
PH12017500029A1 (en) | 4,5-dihydroisoxazole derivatives as nampt inhibitors | |
JOP20220156A1 (ar) | مشتقات فوروإندازول | |
JP2017532357A5 (hr) | ||
NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
AR112471A1 (es) | Antagonistas del receptor del factor liberador de corticotropina | |
RU2017124423A (ru) | Соединения дигидропиримидин-2-она и их медицинское применение | |
MX2020008498A (es) | Derivados de sobetirome. | |
CL2016001803A1 (es) | Compuestos derivados de heteroarilos bicíclicos fusionados, agonistas rxr; composición farmacéutica y su uso en el tratamiento del cáncer, diabetes, obesidad, dermatitis, psoriasis, alopecia, queratosis actínica, enfermedades cardiovasculares, metabólicas, hepáticas, cirrosis, enfermedades renales, fibrosis pulmonar, enfermedades oftálmicas, autoinmunes e inflamatorias, alzheimer, párkinson, esclerosis múltiple. | |
MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones |